Novel Compound Opens New Avenue in Immunotherapy Treatment for Cancers
Researchers at the UF Health Cancer Center have developed a first-of-it-kind compound that may reveal a new way to treat cancer using immunotherapy. Currently, immunotherapy is among the most groundbreaking cancer treatments, but only about 20% to 40% of patients respond to it. It works by first identifying a target protein that contributes to tumor development and then developing a compound that will target that protein specifically, slowing tumor growth and boosting the body's immune system to fight off the cancer.
Dr. Castillo Caro Accepted into Early Investigator Advancement Program
Paul Castillo, M.D., was recently accepted into the National Cancer Institute's Early Investigator Advancement Program. The program aims to bolster expertise and offer guidance for investigators to create competitive grant applications.
Tech Tuesday – Barry Byrne
In this week’s Tech Tuesday for WCJB TV20, UF Innovate’s Loren Miranda speaks with Dr. Barry Byrne, Associate Chair of Pediatrics and Director of the UF Powell Gene Therapy Center.
University of Florida Researchers Unlock New Frontiers in Brain Tumor Treatments
Researchers at the University of Florida's are making breakthroughs in the treatment of malignant brain tumors. Duane Mitchell, M.D., Ph.D., co-directs the teams conducting this research at the Preston A. Well Jr. Center for Brain Tumor Therapy at UF Health. Over the past ten years, the center has received FDA approval on 12 therapeutics and launched 13 novel immunotherapy clinical trials.
UF Health Cancer Center to Launch Mobile Mammography Unit and Expand Access to Care
With a $1.5-million grant awarded through University of Florida President Ben Sasse’s strategic funding initiative, the UF Health Cancer Center will launch an initiative called Expanding Access to Breast Cancer Screening in North Central Florida. A mobile mammography unit will be outfitted with leading-edge technology to bring services directly to the community. The unit will be the first of its kind in North Central Florida – a region larger than Massachusetts, Rhode Island, and Connecticut combined.
Genetic Score Advances Personalized Treatment Strategies With Promising AML Drug
In the latest development in precision medicine approaches to treating pediatric leukemia, UF Health researchers have developed a genetic score to predict patient outcomes with a promising targeted drug treatment.
Novel ‘Chimera’ Drug Targets the ‘Undruggable’ Parkinson’s Protein
Researchers at The Herbert Wertheim UF Scripps Institute in Jupiter, FL have created a "two-headed" drug nicknamed Chimera due to its ability to target RNA machinery as well as the toxic protein that causes Parkinson's disease.
New Study Findings Could Be Key to Early Detection, Prognosis Prediction in Sepsis
A new study by seven major university medical centers, led by the University of Florida, has identified a way to predict within four days of admission whether a septic patient is at an increased risk of dying. These findings will allow patients to be given the proper care sooner, and allows health care professionals to monitor their immune suppression during care.
Tech Tuesday – Mei He
In this week's Tech Tuesday for WCJB TV20, UF Innovate's Melanie Morón interviews Mei He, associate professor in the UF College of Pharmacy. Her research focuses on advancing the delivery of drugs to the human body.
By utilizing naturally-derived materials, the drug delivery process is more efficient and the drug's efficacy is maximized.
Atsena Therapeutics Announces Positive 12-Month Safety and Efficacy Data From Ongoing Phase I/II Clinical Trial To Treat Leber Congenital Amaurosis
Atsena Therapeutics announced positive results in their 12-month safety and efficacy data from the ongoing Phase I/II trial of ATSN-101, the company’s investigational gene therapy for the treatment of GUCY2D-associated Leber congenital amaurosis (LCA1). At 12 months post-treatment, ATSN-101 has conferred clinically meaningful improvements in vision at the highest dose with no serious treatment-emergent adverse events.
